An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients

Hidenori Takahashi, Mitsuhiko Kawaguchi, Kunihiro Kitamura, Seiji Narumiya, Munenori Kawamura, Isamu Tengan, Shinji Nishimoto, Yasuo Hanamure, Yasuo Majima, Shuichi Tsubura, Kiichiro Teruya, Sanetaka Shirahata

研究成果: ジャーナルへの寄稿記事

9 引用 (Scopus)

抄録

Background. Conventional anticancer therapies still cause difficulties with selective eradication and accompanying side effects that reduce patients’ quality of life (QOL). Fucoidan is extracted from seaweeds and has already exhibited broad bioactivities, including anticancer and anti-inflammatory properties, in basic studies. It is expected to enhance therapeutic efficacy and minimize side effects in cancer patients; however, despite its potential benefits, there are very few clinical trials using fucoidans. Therefore, we performed an exploratory clinical study for advanced cancer patients to examine the efficacy of fucoidans, especially focusing on inflammation in relation to QOL scores. Methods. We conducted a prospective, open-label clinical study for advanced cancer patients using fucoidans via oral administration; 20 advanced cancer patients with metastases were recruited and were given 400 mL/d fucoidan (10 mg/mL) for at least 4 weeks. Inflammatory biomarkers, including high-sensitivity C-reactive protein and various cytokines, and QOL scores were monitored before treatment, after 2 weeks, and after 4 weeks of fucoidan ingestion. Results. The main proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were significantly reduced after 2 weeks of fucoidan ingestion. QOL scores, including fatigue, stayed almost stable without significant changes during the study period. The univariate and multivariate analyses revealed that the responsiveness of IL-1β was a significant independent prognostic factor. Conclusion. This is the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients. In future studies, larger blinded, controlled trials are required to establish the efficacy of fucoidan as supportive care for cancer patients, especially those undergoing chemotherapy.

元の言語英語
ページ(範囲)282-291
ページ数10
ジャーナルIntegrative Cancer Therapies
17
発行部数2
DOI
出版物ステータス出版済み - 6 1 2018

Fingerprint

Anti-Inflammatory Agents
Quality of Life
Neoplasms
Interleukin-1
Eating
Cytokines
fucoidan
Seaweed
C-Reactive Protein
Fatigue
Oral Administration
Interleukin-6
Patient Care
Therapeutics
Multivariate Analysis
Tumor Necrosis Factor-alpha
Biomarkers
Clinical Trials
Neoplasm Metastasis
Inflammation

All Science Journal Classification (ASJC) codes

  • Oncology
  • Complementary and alternative medicine

これを引用

Takahashi, H., Kawaguchi, M., Kitamura, K., Narumiya, S., Kawamura, M., Tengan, I., ... Shirahata, S. (2018). An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients. Integrative Cancer Therapies, 17(2), 282-291. https://doi.org/10.1177/1534735417692097

An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients. / Takahashi, Hidenori; Kawaguchi, Mitsuhiko; Kitamura, Kunihiro; Narumiya, Seiji; Kawamura, Munenori; Tengan, Isamu; Nishimoto, Shinji; Hanamure, Yasuo; Majima, Yasuo; Tsubura, Shuichi; Teruya, Kiichiro; Shirahata, Sanetaka.

:: Integrative Cancer Therapies, 巻 17, 番号 2, 01.06.2018, p. 282-291.

研究成果: ジャーナルへの寄稿記事

Takahashi, H, Kawaguchi, M, Kitamura, K, Narumiya, S, Kawamura, M, Tengan, I, Nishimoto, S, Hanamure, Y, Majima, Y, Tsubura, S, Teruya, K & Shirahata, S 2018, 'An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients', Integrative Cancer Therapies, 巻. 17, 番号 2, pp. 282-291. https://doi.org/10.1177/1534735417692097
Takahashi, Hidenori ; Kawaguchi, Mitsuhiko ; Kitamura, Kunihiro ; Narumiya, Seiji ; Kawamura, Munenori ; Tengan, Isamu ; Nishimoto, Shinji ; Hanamure, Yasuo ; Majima, Yasuo ; Tsubura, Shuichi ; Teruya, Kiichiro ; Shirahata, Sanetaka. / An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients. :: Integrative Cancer Therapies. 2018 ; 巻 17, 番号 2. pp. 282-291.
@article{9be76a4ed6984035803499570eebd936,
title = "An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients",
abstract = "Background. Conventional anticancer therapies still cause difficulties with selective eradication and accompanying side effects that reduce patients’ quality of life (QOL). Fucoidan is extracted from seaweeds and has already exhibited broad bioactivities, including anticancer and anti-inflammatory properties, in basic studies. It is expected to enhance therapeutic efficacy and minimize side effects in cancer patients; however, despite its potential benefits, there are very few clinical trials using fucoidans. Therefore, we performed an exploratory clinical study for advanced cancer patients to examine the efficacy of fucoidans, especially focusing on inflammation in relation to QOL scores. Methods. We conducted a prospective, open-label clinical study for advanced cancer patients using fucoidans via oral administration; 20 advanced cancer patients with metastases were recruited and were given 400 mL/d fucoidan (10 mg/mL) for at least 4 weeks. Inflammatory biomarkers, including high-sensitivity C-reactive protein and various cytokines, and QOL scores were monitored before treatment, after 2 weeks, and after 4 weeks of fucoidan ingestion. Results. The main proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were significantly reduced after 2 weeks of fucoidan ingestion. QOL scores, including fatigue, stayed almost stable without significant changes during the study period. The univariate and multivariate analyses revealed that the responsiveness of IL-1β was a significant independent prognostic factor. Conclusion. This is the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients. In future studies, larger blinded, controlled trials are required to establish the efficacy of fucoidan as supportive care for cancer patients, especially those undergoing chemotherapy.",
author = "Hidenori Takahashi and Mitsuhiko Kawaguchi and Kunihiro Kitamura and Seiji Narumiya and Munenori Kawamura and Isamu Tengan and Shinji Nishimoto and Yasuo Hanamure and Yasuo Majima and Shuichi Tsubura and Kiichiro Teruya and Sanetaka Shirahata",
year = "2018",
month = "6",
day = "1",
doi = "10.1177/1534735417692097",
language = "English",
volume = "17",
pages = "282--291",
journal = "Integrative Cancer Therapies",
issn = "1534-7354",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - An Exploratory Study on the Anti-inflammatory Effects of Fucoidan in Relation to Quality of Life in Advanced Cancer Patients

AU - Takahashi, Hidenori

AU - Kawaguchi, Mitsuhiko

AU - Kitamura, Kunihiro

AU - Narumiya, Seiji

AU - Kawamura, Munenori

AU - Tengan, Isamu

AU - Nishimoto, Shinji

AU - Hanamure, Yasuo

AU - Majima, Yasuo

AU - Tsubura, Shuichi

AU - Teruya, Kiichiro

AU - Shirahata, Sanetaka

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background. Conventional anticancer therapies still cause difficulties with selective eradication and accompanying side effects that reduce patients’ quality of life (QOL). Fucoidan is extracted from seaweeds and has already exhibited broad bioactivities, including anticancer and anti-inflammatory properties, in basic studies. It is expected to enhance therapeutic efficacy and minimize side effects in cancer patients; however, despite its potential benefits, there are very few clinical trials using fucoidans. Therefore, we performed an exploratory clinical study for advanced cancer patients to examine the efficacy of fucoidans, especially focusing on inflammation in relation to QOL scores. Methods. We conducted a prospective, open-label clinical study for advanced cancer patients using fucoidans via oral administration; 20 advanced cancer patients with metastases were recruited and were given 400 mL/d fucoidan (10 mg/mL) for at least 4 weeks. Inflammatory biomarkers, including high-sensitivity C-reactive protein and various cytokines, and QOL scores were monitored before treatment, after 2 weeks, and after 4 weeks of fucoidan ingestion. Results. The main proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were significantly reduced after 2 weeks of fucoidan ingestion. QOL scores, including fatigue, stayed almost stable without significant changes during the study period. The univariate and multivariate analyses revealed that the responsiveness of IL-1β was a significant independent prognostic factor. Conclusion. This is the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients. In future studies, larger blinded, controlled trials are required to establish the efficacy of fucoidan as supportive care for cancer patients, especially those undergoing chemotherapy.

AB - Background. Conventional anticancer therapies still cause difficulties with selective eradication and accompanying side effects that reduce patients’ quality of life (QOL). Fucoidan is extracted from seaweeds and has already exhibited broad bioactivities, including anticancer and anti-inflammatory properties, in basic studies. It is expected to enhance therapeutic efficacy and minimize side effects in cancer patients; however, despite its potential benefits, there are very few clinical trials using fucoidans. Therefore, we performed an exploratory clinical study for advanced cancer patients to examine the efficacy of fucoidans, especially focusing on inflammation in relation to QOL scores. Methods. We conducted a prospective, open-label clinical study for advanced cancer patients using fucoidans via oral administration; 20 advanced cancer patients with metastases were recruited and were given 400 mL/d fucoidan (10 mg/mL) for at least 4 weeks. Inflammatory biomarkers, including high-sensitivity C-reactive protein and various cytokines, and QOL scores were monitored before treatment, after 2 weeks, and after 4 weeks of fucoidan ingestion. Results. The main proinflammatory cytokines, including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) were significantly reduced after 2 weeks of fucoidan ingestion. QOL scores, including fatigue, stayed almost stable without significant changes during the study period. The univariate and multivariate analyses revealed that the responsiveness of IL-1β was a significant independent prognostic factor. Conclusion. This is the first study providing evidence of the anti-inflammatory effects of fucoidans for advanced cancer patients. In future studies, larger blinded, controlled trials are required to establish the efficacy of fucoidan as supportive care for cancer patients, especially those undergoing chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85047011894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047011894&partnerID=8YFLogxK

U2 - 10.1177/1534735417692097

DO - 10.1177/1534735417692097

M3 - Article

VL - 17

SP - 282

EP - 291

JO - Integrative Cancer Therapies

JF - Integrative Cancer Therapies

SN - 1534-7354

IS - 2

ER -